ATP citrate lyase Antibody [N17N8]

Application: Reactivity: Human, Mouse, Rat

Lane 1: MCF7, Lane 2: Hela, Lane 3: HepG2

Usage Information

Dilution
WB1:1000

Application
WB

Reactivity
Human, Mouse, Rat

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
125 kDa

Datasheet & SDS

Biological Description

Specificity
ATP citrate lyase Antibody [N17N8] detects endogenous levels of total ATP citrate lyase protein.

Clone
N17N8

Synonym(s)
ACLY; ATP-citrate synthase; EC:2.3.3.8; ATP-citrate (pro-S-)-lyase (ACL); Citrate cleavage enzyme

Background
ATP citrate lyase (ACLY), a cytosolic homotetrameric enzyme at the interface of glucose and lipid metabolism, cleaves citrate derived from mitochondrial export into acetyl-CoA and oxaloacetate to fuel de novo lipogenesis, cholesterol synthesis, and histone acetylation, organized into two major domains per subunit, an N-terminal citrate synthase-homology (CSH) domain encompassing residues ~1-700 that binds citrate and CoA to form citryl-CoA via His760 loop swinging and pantothenate arm translocation, coordinated with a C-terminal ATP-grasp citrate lyase-like (CL) domain (~700-1105) housing the nucleotide-binding site where Mg²⁺-ATP phosphorylation occurs through Asp938 and Lys828 stabilization of the γ-phosphate transfer in a sequential ordered Bi Bi mechanism, breaking D2 symmetry across subunits for energetic coupling during conformational shifts from apo (open CCS) to compact intermediate states with citryl-1-phosphate and CoA at the CCS catalytic center (G281-283, S308, E599, G664-665). ACLY drives anabolic pathways by delivering acetyl-CoA for fatty acid synthase and HMGCR in nutrient-rich conditions via SREBP-1/2 activation, undergoes Akt-mediated Ser455 phosphorylation to relieve citrate allostery and boost Vmax by 3-fold while favoring ATP over CTP, couples with ACSS2 for acetate salvage during hypoxia/glucose restriction to sustain proliferation, and interfaces with epigenetics through nuclear translocation for H3K27ac at promoters of MYC/IGF2 in cancer cells, with subunit conformational barriers (His760 loops, radius of gyration drop at catalytic center formation) synchronized to biochemical steps, citrate phosphorylation, citryl-CoA formation, and cleavage, enabling ~10⁶-fold rate acceleration. Dysregulated ACLY overexpression fuels metabolic reprogramming in tumors (breast, prostate, glioblastoma) via PI3K/AKT/mTORC1 hyperactivation, promotes hepatic steatosis under high-fructose diets through ChREBP induction, and its inhibition by bempedoic acid or ND-630 reduces LDL-C and tumor growth by starving lipogenesis without impairing ketogenesis.

Background

ATP citrate lyase (ACLY), a cytosolic homotetrameric enzyme at the interface of glucose and lipid metabolism, cleaves citrate derived from mitochondrial export into acetyl-CoA and oxaloacetate to fuel de novo lipogenesis, cholesterol synthesis, and histone acetylation, organized into two major domains per subunit, an N-terminal citrate synthase-homology (CSH) domain encompassing residues ~1-700 that binds citrate and CoA to form citryl-CoA via His760 loop swinging and pantothenate arm translocation, coordinated with a C-terminal ATP-grasp citrate lyase-like (CL) domain (~700-1105) housing the nucleotide-binding site where Mg²⁺-ATP phosphorylation occurs through Asp938 and Lys828 stabilization of the γ-phosphate transfer in a sequential ordered Bi Bi mechanism, breaking D2 symmetry across subunits for energetic coupling during conformational shifts from apo (open CCS) to compact intermediate states with citryl-1-phosphate and CoA at the CCS catalytic center (G281-283, S308, E599, G664-665). ACLY drives anabolic pathways by delivering acetyl-CoA for fatty acid synthase and HMGCR in nutrient-rich conditions via SREBP-1/2 activation, undergoes Akt-mediated Ser455 phosphorylation to relieve citrate allostery and boost Vmax by 3-fold while favoring ATP over CTP, couples with ACSS2 for acetate salvage during hypoxia/glucose restriction to sustain proliferation, and interfaces with epigenetics through nuclear translocation for H3K27ac at promoters of MYC/IGF2 in cancer cells, with subunit conformational barriers (His760 loops, radius of gyration drop at catalytic center formation) synchronized to biochemical steps, citrate phosphorylation, citryl-CoA formation, and cleavage, enabling ~10⁶-fold rate acceleration. Dysregulated ACLY overexpression fuels metabolic reprogramming in tumors (breast, prostate, glioblastoma) via PI3K/AKT/mTORC1 hyperactivation, promotes hepatic steatosis under high-fructose diets through ChREBP induction, and its inhibition by bempedoic acid or ND-630 reduces LDL-C and tumor growth by starving lipogenesis without impairing ketogenesis.

References
https://pubmed.ncbi.nlm.nih.gov/31873304/ https://pubmed.ncbi.nlm.nih.gov/20558738/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%